|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Arnould L et al. Pathological complete response to trastuzumab-based neoadjuvant
therapy is related to the level of HER2 amplification in locally advanced breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 1033.
Bacus SS et al. Inhibition of ErbB1/2 by small molecule tyrosine kinase inhibitors, but not trastuzumab, affects metabolic pathways: Implications to cardiac toxicity. San Antonio Breast Cancer Symposium 2006;Abstract 304.
Buzdar AU et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13(1):228-33. Abstract
Buzdar AU et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676-85. Abstract
Cristofanilli M et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). San Antonio Breast Cancer Symposium 2006;Abstract 1.
Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43. Abstract
Hurley J et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for
human epidermal growth factor receptor 2-positive locally advanced breast cancer.
J Clin Oncol 2006;24(12):1831-8. Abstract
Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or
without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Konecny GE et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66(3):1630-9. Abstract
Mackey JR et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 3.
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Pietras RJ et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10(12):2435-46. Abstract
Robert N et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24(18):2786-92. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC 
T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Smith I et al; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract
 |
 |
